Company intelligence
PONS
Bringing Ultrasound to the mass market with AI to provide high-quality ultrasound data for early diagnosis of cancer
About PONS
Our mission at PONS is to optimize access to healthcare and improve the quality of life for all individuals, irrespective of their location, race, or income. We aim to ensure that no one loses their loved ones prematurely due to preventable diseases. To achieve this, we enhance the capabilities of widely available ultrasound devices by integrating them with cloud-connected artificial intelligence. This innovation addresses the common limitations of imaging that hinder early disease detection and preventive screening. Through software advancements, we unlock a new era of proactive, personalized care, enabling healthcare providers to deliver effective and timely diagnostics. PONS` device-agnostic, patented software and AI models to optimize ultrasound imaging quality, augment tissue contrast, and reduce signal noise while revealing anatomical and pathological features, structural delineations, and microenvironmental context that remain undetectable with conventional ultrasound systems. PONS` patented technology can implement digital contrast without needing chemical contrast injected into the patients, revailing the surrounding on the earliest stages, Our proprietary deep learning algorithms quantitatively analyze temporal variations in morphological and spatial parameters—including tissue geometry, volumetric dimensions, location, surrounding and positional dynamics—to generate AI-powered diagnostic risk assessment reports.
Verified activity
Signals from PONS
7 published signals
Research & Knowledge
PONS co-founder and CTO Prof. Ilker Hacihaliloglu highlighted his work on the PONS Scan in Place for senior care in an article featuring the AARP AgeTech Collaborative.
Reported by PONS
Research & Knowledge
PONS published a paper by Evinova's president reviewing AZ protocols across oncology, respiratory and cardiovascular disease concluding that 74 to 85 percent of trial assessments could be collected remotely, cutting clinical visits by up to 40 percent, published in Nature Medicine in 2023.
Reported by PONS
Partnerships
PONS is one of the 12 companies chosen for a program by Mayo Clinic Platform.
Reported by PONS
Presence & Recognition
PONS team will present three accepted works at the MICCAI Society 2026 conference in Strasbourg, France.
Reported by Ilker Hacihaliloglu
Partnerships
PONS has been selected as one of 12 companies participating in the inaugural multiyear pathway of the Mayo Clinic Platform Accelerate program.
Reported by Ilker Hacihaliloglu
Presence & Recognition
PONS Advisory Board member Harvey Castro, MD, MBA, was named one of the Top 100 Most Influential People in HealthTech
Reported by PONS
Products & Services
PONS built software that processes images already owned by users to compute lesion boundaries and internal structure using physics-based methods, generating up to 50 distinct versions from each source image.
Reported by PONS